Followers | 195 |
Posts | 24601 |
Boards Moderated | 0 |
Alias Born | 04/03/2010 |
Saturday, March 04, 2017 10:51:46 AM
If it's FUTILE, you don't keep giving patients false hope by continuing giving them a futile treatment. That would be NONSENSE. You don't let placebo patients cross over, if the treatment is futile. And absolutely NO REGULATORY AGENCY WOULD DO THIS. It's profoundly ignornat to make such a suggestion.
No, they actually do the opposite. They make a declaration of futility.
However, when a treatment is showing overwhelming efficacy, they do a partial halt to prevent having more placebo patients because you are then knowingly subjecting them to incredible risk that is unnecessary. In fact, this is a real thing with crossover trials I have come to understand.
Now, I will be clear. I don't yet know the reason for the halt. I do know that the gentleman that resigned (looks like RETIRED is the more appropriate description) from the DSMB is a recognized expert, and he places high value on his willingness to break with convention and tell the truth, without view to the consequences. Meanwhile, it took two searches for me to get basic information on him and most likely why he resigned. But those who would impugn NWBO posted that he had resigned, without information, I think, to suggest it indicated a problem. No information was given, but the implication was he must've resigned in protest. That kind of posting, which is common to a certain set, is really the problem in terms of creating and fomenting false controversy and fake news with trials for many biotechs. There is a subset of speculators who trade in this kind of activity. That's how they make their money.
I do know that the story is not as simple as those who are naysayers wish to make it.
I know that agencies around the world are allowing this treatment to be administered and did so during the halt and were also going to allow it to be included in new trials.
None of this is consistent with your view. NONE of it.
That's a nice graphic you added, by the way, with the Guy Fawkes mask. But seriously, given your consistency in arguing, despite the facts, on point, after point, after point, when you're not an investor, you say, how is it not representative of your own position?
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED DaBaby and Stunna 4 Vegas's "NO DRIBBLE" Joins Music Licensing, Inc.'s Portfolio • Jun 7, 2024 10:15 AM
Mushrooms Inc. (OTC: MSRM) Announces Significant Share Buy Back by the Board Director and New Strategic Initiatives. • MSRM • Jun 5, 2024 1:32 PM
Hydromer Announces Launch of HydroThrombX Medical Device Coating Technology • HYDI • Jun 5, 2024 10:24 AM
Dr. Michael Dent Finances $1 Million to Drive HealthLynked's Healthcare Transformation • HLYK • Jun 5, 2024 8:00 AM
Avant Technologies Enters Binding LOI to Purchase Dozens of High-Performance, Immersible, AI-Powered Servers • AVAI • Jun 5, 2024 8:00 AM
IQST - iQSTEL Announces $290 Million 2024 Annual Revenue Forecast • IQST • Jun 4, 2024 1:43 PM